Patent ID: 9572878
Date: 2017-02-21
CPC Classifications: A61K,A61P

Claim:
1. A method for the treatment of a c-Met-induced or EGFR-induced cancer, comprising co-administering a pharmaceutically effective amount of (a) a small-molecule EGFR inhibitor and (b) an anti-c-Met antibody or antigen-binding fragment thereof to a subject in need thereof, wherein the anti c-Met antibody or the antigen-binding fragment thereof comprises a complementarity determining region H1 (CDR-H1) comprising the amino acid sequence of SEQ ID NO: 1, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2, a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3, a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 10, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 11, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 13.